Researchers find biomarker for early onset GVHD after transplant

01/8/2010 | Science News

Researchers have discovered that a protein called elafin showed up in greater concentrations among bone marrow transplant patients who exhibited a skin rash after the procedure and developed graft-versus-host disease later on compared with those who did not develop the disease. The new protein biomarker could help determine whether skin rash is a sign of early developing GVHD after bone marrow transplant, as well as identify the patients who need more aggressive treatment, the researchers said.

View Full Article in:

Science News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR